# US 2026/0041655 A1 · Papd5 inhibitors, pharmaceutical compositions, and methods of treating neurological and cognitive disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0041655 A1
- Document ID: US20260041655A1
- Status: Published application
- Kind: A1
- Application number: 19/296,311
- Filed: 2025-08-11
- Published: 2026-02-12
- Earliest claimed: 2024-08-09
- Assignees: Miralogx LLC
- Applicants: Miralogx LLC
- Inventors: Jonnie R. Williams, SR.
- Web page: https://patentgrep.com/patent/US20260041655A1

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- C07C 211/40: containing only non-condensed rings
- C07C 311/14: Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Pharmaceutical compounds are useful for treating neurological and cognitive disorders such as Alzheimer's disease. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating a neurological disorder, cognitive disorder or a disorder associated with chronic inflammation involves administering the pharmaceutical composition to an individual in need thereof.

## Claims

### Claim 1

A compound having a structure of Formula (I):
wherein R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of an electron pair, H, halogen, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, carboxylate, carboxyl, ester, hydroperoxy, peroxy, ether, hemiacetal, hemiketal, acetal, ketal, orthoester, methylenedioxy, orthocarbonate ester, carboxamide, amine, imine, amide, azide, azo, cyanate, nitrate, nitrile, isonitrile, nitrosooxy, nitro, pyridyl, thiol, sulfide, sulfinyl, sulfonyl, thiocyanate, carbonothioyl, phosphate, and heterocycle; optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle; wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl; wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl; wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl;
R9 is H or
wherein each is a single bond or a double bond, with the proviso that within a five-membered ring one or two is a double bond and the remaining are single bonds; and wherein X is an electron pair, CH2, SO2 or
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein at least one of R1, R2, R3, R4, R5, R6, R7 and R5 is a halogen.

### Claim 3 (depends on 2)

The compound of claim 2 wherein the halogen is independently selected from the group consisting of fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

### Claim 4 (depends on 3)

The compound of claim 3 wherein the halogen is independently selected from the group consisting of F and Cl.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R2 is Cl.

### Claim 6 (depends on 5)

The compound of claim 5 wherein each of R3 and R7 is F.

### Claim 7 (depends on 1)

A pharmaceutical composition comprises a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, ester, or ether thereof, and a pharmaceutically acceptable vehicle therefor.

### Claim 8 (depends on 7)

A method of treating an age-related or cognitive disorder comprises administering to an individual in need thereof a pharmaceutical composition of claim 7.

### Claim 9 (depends on 7)

A method of treating a disorder associated with chronic inflammation comprising administering to an individual in need thereof the pharmaceutical composition of claim 7.

### Claim 10 (depends on 1)

A compound of claim 1 which has a structure according to Formula (II):
wherein each is independently a single bond or a double bond;
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 11 (depends on 1)

A compound of claim 1 which has a structure according to Formula (III):
wherein each is independently a single bond or a double bond;
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 12 (depends on 11)

A pharmaceutical composition comprises a therapeutically effective amount of a compound of claim 11, or a pharmaceutically acceptable salt, ester, or ether thereof, and a pharmaceutically acceptable vehicle therefor.

### Claim 13 (depends on 12)

A method of treating an age-related or cognitive disorder comprises administering to an individual in need thereof a pharmaceutical composition of claim 12.

### Claim 14 (depends on 12)

A method of treating a disorder associated with chronic inflammation comprising administering to an individual in need thereof the pharmaceutical composition of claim 12.

### Claim 15

A compound having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 16 (depends on 15)

A pharmaceutical composition comprises a therapeutically effective amount of a compound of claim 15, or a pharmaceutically acceptable salt, ester, or ether thereof, and a pharmaceutically acceptable vehicle therefor.

### Claim 17 (depends on 16)

A method of treating an age-related or cognitive disorder comprises administering to an individual in need thereof a pharmaceutical composition of claim 16.

### Claim 18 (depends on 16)

A method of treating a disorder associated with chronic inflammation comprising administering to an individual in need thereof the pharmaceutical composition of claim 16.
